推薦產品
物種活性
human
包裝
kit of 96 wells (12 strips x 8 wells)
技術
ELISA: suitable
capture ELISA: suitable
輸入
sample type cell culture supernatant(s)
sample type serum
sample type plasma
sample type urine
assay range
inter-assay cv: <12%
intra-assay cv: <10%
sensitivity: 2 pg/mL
standard curve range: 1.1-800 pg/mL
檢測方法
colorimetric
運輸包裝
wet ice
儲存溫度
−20°C
基因資訊
human ... GDF15(9518)
一般說明
人生长分化因子15/巨噬细胞抑制因子1(GDF-15/MIC-1)的ELISA（酶联免疫吸附测定）试剂盒通过体外酶联免疫吸附技术定量测定血清、血浆、细胞培养物上清、尿液或细胞和组织裂解液等生物样本中的目标蛋白。生长分化因子15(GDF-15)是应激反应的细胞因子。在炎症反应和组织损伤过程中浓度升高。GDF-15与代谢性心血管病风险有关。它位于脂肪细胞、巨噬细胞、心肌细胞和血管平滑肌细胞中。
免疫原
重组人GDF15
應用
人生长分化因子15/巨噬细胞抑制因子1(GDF-15/MIC-1)ELISA（酶联免疫吸附测定）试剂盒已用于定量测定静脉血样本中的循环巨噬细胞抑制因子-1(MIC-1)。
仅供研究使用。不可用于诊断操作。
请参考附带的一般ELISA试剂盒操作程序（夹心、竞争性 & 间接ELISA）
请参考附带的一般ELISA试剂盒操作程序（夹心、竞争性 & 间接ELISA）
其他說明
本产品提供样本检验报告。
请在批号对应的文本框中输入样品 一词。
请在批号对应的文本框中输入样品 一词。
訊號詞
Warning
危險聲明
防範說明
危險分類
Met. Corr. 1
儲存類別代碼
8A - Combustible, corrosive hazardous materials
水污染物質分類（WGK）
WGK 3
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
Increased expression of GDF-15 may mediate ICU-acquired weakness by down-regulating muscle microRNAs.
Bloch SA
Thorax, 70(3), 219-228 (2015)
Hilde Engerud et al.
PloS one, 14(1), e0210585-e0210585 (2019-01-16)
Better biomarkers are needed in order to identify patients with endometrial carcinoma at risk of recurrence and who may profit from a more aggressive treatment regimen. Our objective was to explore the applicability of plasma growth differentiation factor 15 (GDF-15)
Azza Abdel Gawad Tantawy et al.
Blood cells, molecules & diseases, 53(4), 189-193 (2014-07-30)
High expression of growth differentiation factor-15 (GDF-15) contributes to pathological iron overload in thalassemia. Sickle cell syndromes are characterized by increased levels of erythropoiesis, although the primary defect involves the destruction of mature erythrocytes. To determine serum GDF-15 in 35
Sébastien Jeay et al.
Cancer research, 78(21), 6257-6267 (2018-08-24)
Activation of p53 by inhibitors of the p53-MDM2 interaction is being pursued as a therapeutic strategy in p53 wild-type cancers. Here, we report distinct mechanisms by which the novel, potent, and selective inhibitor of the p53-MDM2 interaction HDM201 elicits therapeutic
Insulin resistance, type 1 and type 2 diabetes, and related complications 2015
Ndisang J F, et al.
Journal of Diabetes Research (2015)
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務